| UHC UMR Medical and Drug | Natalizumab (Tyruko® & Tysabri®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | Hyaluronate Derivatives (Viscosupplementation) | 2026-01-01 |
| Ambetter Health Texas Superior Medicaid Clinical | D. Centene clinical policy | 2026-01-01 |
| BCBS Iowa Medical Policies | Cosmetic and Reconstructive Services | 2026-01-01 |
| BCBS Iowa Medical Policies | Elevidys | 2026-01-01 |
| BCBS Iowa Medical Policies | Gender Affirming Services | 2026-01-01 |
| BCBS Iowa Medical Policies | Injection Therapy for Headache Management | 2026-01-01 |
| BCBS Iowa Medical Policies | Leqembi | 2026-01-01 |
| BCBS Iowa Medical Policies | Lutathera (Lutetium Lu 177 Dotatate)* | 2026-01-01 |
| BCBS Iowa Medical Policies | Miscellaneous Treatments for Varicose Veins/Venous Insufficiency | 2026-01-01 |